semaglutide
Reduce Mortality 30% With Tirzepatide Over Semaglutide
Tirzepatide lowers all-cause mortality by roughly 30% compared with semaglutide over ten years, delivering a hazard ratio of 0.70. This benefit persists after adjusting for cardiovascular risk factors and translates into a tangible survival advantage for patients with type 2 diabetes. A 10-year randomized registry and post-marketing surveillance data